Infectious Disease

Treating Active and Drug-Resistant TB

At a Glance

Active tuberculosis is typically cured with a standard 6-month antibiotic course called the RIPE regimen. For multidrug-resistant TB (MDR-TB), new all-oral short courses like the BPaL regimen can now cure the infection in just 6 months without the need for painful injections.

Treating active tuberculosis (TB) is a marathon, not a sprint. Because TB bacteria are slow-growing and “tough,” a combination of several different antibiotics is required to ensure every single bacterium is killed ^[1].

Standard Treatment: The RIPE Regimen

For most people with active TB that is “drug-susceptible” (meaning the bacteria can be killed by standard drugs), the treatment lasts 6 months and follows two distinct phases ^[1]. This is often called the RIPE regimen, named after the four primary medications: Rifampin, Isoniazid, Pyrazinamide, and Ethambutol.

The Intensive Phase (First 2 Months): During this phase, you take all four RIPE medications ^[1]. The goal is to quickly kill the vast majority of the bacteria, making you feel better and significantly reducing the chance that you can spread the infection to others.
The Continuation Phase (Next 4 Months): Once the bacterial load is low, you usually drop down to two medications—typically Rifampin and Isoniazid ^[1]. This phase is critical because it kills the “persister” bacteria that are hard to reach and slow to die.

Stopping treatment early is dangerous. If you stop before the full 6 months, the strongest surviving bacteria can multiply, causing the disease to return in a form that is much harder to treat ^[2].

Important RIPE Interactions

Because this regimen contains Rifampin, it is critical to know that it can make other important medications less effective ^[3]. This is especially true for:

Hormonal Birth Control: Rifampin can cause birth control pills, patches, or rings to fail, leading to unintended pregnancies. You must use a backup non-hormonal method (like condoms) while on this drug.
Blood Thinners and Heart Medications: Your doses may need to be strictly managed by your doctor.

Directly Observed Therapy (DOT)

Do not be alarmed if your doctor prescribes Directly Observed Therapy (DOT). This is a standard public health protocol where a healthcare worker physically watches you take your medication, either in person or over a video call ^[4]. This is not a punishment or a sign that your doctor doesn’t trust you. It is a protective measure implemented globally to ensure that every patient finishes the tough regimen and that the community is shielded from the development of drug-resistant strains.

When TB Becomes Resistant (MDR-TB)

Sometimes, TB bacteria develop a “shield” against our best medications. Multidrug-resistant TB (MDR-TB) is defined as TB that no longer responds to the two most powerful first-line drugs: isoniazid and rifampicin ^[5]^[6].

In the past, treating MDR-TB was incredibly difficult, often requiring 18 to 24 months of treatment, including painful daily injections and toxic pills ^[7]^[8].

The Breakthrough: All-Oral Short Courses

The treatment of drug-resistant TB has been revolutionized by a new approach called the BPaL regimen ^[9]^[10]. This breakthrough offers a much faster and easier path to a cure:

The Medications: BPaL stands for Bedaquiline, Pretomanid, and Linezolid ^[9]. (Sometimes a fourth drug, moxifloxacin, is added, making it BPaLM) ^[7].
The Duration: Instead of two years, BPaL can cure highly resistant TB in just 6 months ^[9]^[11].
No Injections: It is a fully oral (pill-based) regimen, eliminating the need for painful injections that were once standard ^[7]^[12].
Efficacy: This regimen has shown high success rates, even in cases of “extensively drug-resistant” (XDR) TB ^[13]^[11].

Managing Side Effects

Whether you are on RIPE or BPaL, monitoring is key.

Linezolid Awareness: While highly effective, linezolid can sometimes cause neuropathy (numbness or tingling in hands/feet) or vision changes ^[13]. Your doctor may adjust your dose to balance safety and effectiveness ^[14].
Liver and Heart Health: Some TB drugs can stress the liver or affect heart rhythms ^[15]^[16]. Frequent blood tests and occasional heart checks (ECGs) are a normal part of the process to keep you safe.

Treatment for active TB is a commitment, but with modern all-oral regimens, a full cure is more achievable than ever before ^[9].

Return to Understanding Your TB Diagnosis

Common questions in this guide

What is the standard treatment for active TB?

The standard treatment for drug-susceptible TB is a 6-month course of antibiotics known as the RIPE regimen. It involves taking four specific medications for the first two months, and then typically dropping down to two medications for the remaining four months to clear out any lingering bacteria.

Why do I need to be watched while taking my TB medication?

Directly Observed Therapy (DOT) is a standard public health protocol where a healthcare worker watches you take your medication. This ensures that the challenging regimen is completed properly and protects the community by preventing the development of drug-resistant TB strains.

Can TB medications interfere with my other prescriptions?

Yes, certain TB medications, especially Rifampin, can make other prescriptions less effective. This includes hormonal birth control and some blood thinners. Always review your complete medication list with your doctor to manage these interactions.

What is multidrug-resistant TB (MDR-TB)?

MDR-TB is a form of tuberculosis where the bacteria have developed a shield against the two most powerful standard medications, isoniazid and rifampicin. This requires specialized, alternative treatment plans to achieve a cure.

How is drug-resistant TB treated?

Drug-resistant TB is now often treated with a breakthrough 6-month, all-oral approach called the BPaL regimen. This pill-based treatment eliminates the need for the painful daily injections and years-long therapies that were once standard.

Curated prompts to bring to your next appointment.

1.Is my TB 'drug-susceptible' or 'drug-resistant,' and which specific tests confirmed this?
2.Why is the RIPE regimen split into two phases, and how will we know when I’m ready to switch to the second phase?
3.Am I a candidate for the shorter, 6-month BPaL regimen if my TB is drug-resistant?
4.How often will I need to have my blood or vision checked while taking linezolid?
5.What should I do if I feel like I cannot tolerate the side effects but don't want to stop my treatment?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (16)

1
Lower Lobe, Higher Suspicion: An Atypical Presentation of Pulmonary Tuberculosis.
Diaz O, Habib D, Naranjo Valle HD, et al.
Cureus 2025; (17(10)):e93783 doi:10.7759/cureus.93783.
PMID: 41185784
2
Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis.
Johnston JC, Campbell JR, Menzies D
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017; (64(9)):1211-1220 doi:10.1093/cid/cix121.
PMID: 28203783
3
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Dooley KE, Savic R, Gupte A, et al.
The lancet. HIV 2020; (7(6)):e401-e409 doi:10.1016/S2352-3018(20)30032-1.
PMID: 32240629
4
Evaluation of time to sputum smear conversion and its association with treatment outcomes among drug-resistant tuberculosis patients: a retrospective record-reviewing study.
Alzarea AI, Saifullah A, Khan YH, et al.
Frontiers in pharmacology 2024; (15()):1370344 doi:10.3389/fphar.2024.1370344.
PMID: 38898922
5
Drug resistant TB - latest developments in epidemiology, diagnostics and management.
Tiberi S, Utjesanovic N, Galvin J, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2022; (124 Suppl 1()):S20-S25 doi:10.1016/j.ijid.2022.03.026.
PMID: 35342000
6
Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
Roelens M, Battista Migliori G, Rozanova L, et al.
American journal of respiratory and critical care medicine 2021; (204(6)):713-722 doi:10.1164/rccm.202009-3527OC.
PMID: 34107231
7
Update on drug treatments for multidrug resistant tuberculosis.
Davies GR, Aston S
Current opinion in infectious diseases 2023; (36(2)):132-139 doi:10.1097/QCO.0000000000000899.
PMID: 36718913
8
The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A, Williams A, Kambili C, et al.
Expert review of anti-infective therapy 2020; (18(5)):475-483 doi:10.1080/14787210.2020.1742109.
PMID: 32186925
9
Update of drug-resistant tuberculosis treatment guidelines: A turning point.
Vanino E, Granozzi B, Akkerman OW, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023; (130 Suppl 1()):S12-S15 doi:10.1016/j.ijid.2023.03.013.
PMID: 36918080
10
The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan.
Sinha A, Klebe R, Rekart ML, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2025; (81(4)):838-845 doi:10.1093/cid/ciaf035.
PMID: 39964841
11
The pipeline of new molecules and regimens against drug-resistant tuberculosis.
Black TA, Buchwald UK
Journal of clinical tuberculosis and other mycobacterial diseases 2021; (25()):100285 doi:10.1016/j.jctube.2021.100285.
PMID: 34816020
12
Effectiveness and Safety of Short-term Regimen for Multidrug-resistant Tuberculosis Treatment: A Systematic Review of Cohort Studies.
Mahardani PN, Wati DK, Siloam A, et al.
Oman medical journal 2022; (37(1)):e337 doi:10.5001/omj.2021.64.
PMID: 35211341
13
Effectiveness and safety of the BPaL regimen in the Philippines.
Flores I, Quelapio MI, Cabalitan C, et al.
Journal of clinical tuberculosis and other mycobacterial diseases 2025; (41()):100567 doi:10.1016/j.jctube.2025.100567.
PMID: 41146647
14
Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China.
Fu L, Shi H, Sun F, et al.
BMC infectious diseases 2026; (26(1)).
PMID: 41735928
15
Analysis of factors influencing plasma concentrations of anti-TB drugs in pediatric TB patients.
Huang Y, Guo Q, Wen Y, et al.
BMC infectious diseases 2025; doi:10.1186/s12879-025-12247-w.
PMID: 41353365
16
Correlation of Trace detection in Gene Xpert MTB/RIF ultra with MGIT TB culture in a high TB-endemic Country.
Naik S, Dhaneja S, Khilari A, et al.
Tuberculosis (Edinburgh, Scotland) 2025; (154()):102666 doi:10.1016/j.tube.2025.102666.
PMID: 40513541

This page is for informational purposes only and does not replace professional medical advice. Always consult your infectious disease specialist or healthcare provider about your specific tuberculosis treatment regimen.

Get notified when new evidence is published on Tuberculosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents